Last reviewed · How we verify
Glimepiride and Metformin
Glimepiride stimulates insulin secretion from pancreatic beta cells while metformin reduces hepatic glucose production and improves insulin sensitivity, together lowering blood glucose in type 2 diabetes.
Glimepiride stimulates insulin secretion from pancreatic beta cells while metformin reduces hepatic glucose production and improves insulin sensitivity, together lowering blood glucose in type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Glimepiride and Metformin |
|---|---|
| Also known as | Amaryl, Glista |
| Sponsor | Takeda |
| Drug class | Sulfonylurea + Biguanide combination |
| Target | ATP-sensitive potassium channel (Glimepiride); Complex I of mitochondrial electron transport chain (Metformin) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Glimepiride is a meglitinide that binds to ATP-sensitive potassium channels on beta cells, triggering insulin release in response to glucose. Metformin is a biguanide that decreases hepatic gluconeogenesis and glycogenolysis while enhancing peripheral glucose uptake and insulin sensitivity. The combination addresses both insulin deficiency and insulin resistance in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Gastrointestinal disturbance (nausea, diarrhea, abdominal pain)
- Headache
- Dizziness
- Weight gain
- Lactic acidosis (rare)
Key clinical trials
- Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients (PHASE4)
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes (PHASE4)
- Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure (PHASE3)
- Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients (NA)
- A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria (PHASE4)
- Phase 1 Study of Drug-Drug Interactions Between DWP16001, DWC202407, and DWC202408 in Healthy Adults (PHASE1)
- Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Glimepiride and Metformin CI brief — competitive landscape report
- Glimepiride and Metformin updates RSS · CI watch RSS
- Takeda portfolio CI